Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients
This study is currently recruiting participants.
Verified January 2017 by Andrzej Tomasik MD PhD FESC, Medical University of Silesia
Medical University of Silesia
Polpharma Pharmaceutical Company
Information provided by (Responsible Party):
Andrzej Tomasik MD PhD FESC, Medical University of Silesia
First received: March 2, 2013
Last updated: January 1, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||February 2019|
|Estimated Primary Completion Date:||December 2018 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Tomasik A, Jacheć W, Wojciechowska C, Kawecki D, Białkowska B, Romuk E, Gabrysiak A, Birkner E, Kalarus Z, Nowalany-Kozielska E. Randomized placebo controlled blinded study to assess valsartan efficacy in preventing left ventricle remodeling in patients with dual chamber pacemaker--Rationale and design of the trial. Contemp Clin Trials. 2015 May;42:239-43. doi: 10.1016/j.cct.2015.03.015. Epub 2015 Apr 7.